S&P Futures
4,022.75 +21.50 (+0.54%) Dow Futures
32,592.00 +158.00 (+0.49%) Nasdaq Futures
12,947.00 +56.75 (+0.44%) Russell 2000 Futures
1,761.40 +13.70 (+0.78%) Crude Oil
69.71 +0.45 (+0.65%) Gold
1,968.80 -15.00 (-0.76%)
Helius Medical Technologies, Inc. (26HA.F)
Chart Events
Performance Outlook
| Previous Close | 0.2180 |
| Open | 0.2180 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.2300 - 0.2300 |
| 52 Week Range | 0.1930 - 3.2400 |
| Volume | |
| Avg. Volume | 165 |
| Market Cap | 7.005M |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 26HA.F
Related Research
- American City Business Journals
Lab Notes: Arbutus begins human testing of potential hepatitis B cure
A roundup of recent Philadelphia-area life sciences news, including medical device makers Strados Labs and Helius Medical enter into product deals.
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.001 per share, for each outstanding share of Helius Class A common stock held of record on April 3, 2023. The outstanding shares of Series B Preferred Stock will vo
- GlobeNewswire
Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius’s presence in the region -- NEWTOWN, Pa., March 22, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, and HealthTech Connex Inc. (“HTC”), a leading health technology
